ImmunoMind

2150 Shattuck Avenue Ste. 1300

Berkeley

Developer of an AI-powered infrastructure to support drug development for autoimmune, cancer and orphan diseases. The company’s technology helps to identify predictive biomarkers with single-cell precision, democratizing precision medicine by enabling single-cell guided design of clinical trials for diseases with complex etiology and lack of valid surrogate endpoints.